- Home
- TSI vs HLN Comparison
TSI vs HLN Comparison
Compare TSI & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- HLN
- Stock Information
- Founded
- TSI 1987
- HLN 2022
- Country
- TSI United States
- HLN United Kingdom
- Employees
- TSI N/A
- HLN N/A
- Industry
- TSI Investment Managers
- HLN Package Goods/Cosmetics
- Sector
- TSI Finance
- HLN Consumer Discretionary
- Exchange
- TSI Nasdaq
- HLN Nasdaq
- Market Cap
- TSI 231.3M
- HLN 45.6B
- IPO Year
- TSI N/A
- HLN N/A
- Fundamental
- Price
- TSI $4.90
- HLN $10.80
- Analyst Decision
- TSI
- HLN Buy
- Analyst Count
- TSI 0
- HLN 1
- Target Price
- TSI N/A
- HLN $10.95
- AVG Volume (30 Days)
- TSI 106.8K
- HLN 15.1M
- Earning Date
- TSI 01-01-0001
- HLN 02-27-2025
- Dividend Yield
- TSI 7.46%
- HLN 1.58%
- EPS Growth
- TSI N/A
- HLN 38.94
- EPS
- TSI N/A
- HLN 0.20
- Revenue
- TSI N/A
- HLN $14,062,871,660.00
- Revenue This Year
- TSI N/A
- HLN $4.78
- Revenue Next Year
- TSI N/A
- HLN $4.75
- P/E Ratio
- TSI N/A
- HLN $26.51
- Revenue Growth
- TSI N/A
- HLN N/A
- 52 Week Low
- TSI $4.48
- HLN $8.12
- 52 Week High
- TSI $4.87
- HLN $10.80
- Technical
- Relative Strength Index (RSI)
- TSI 57.57
- HLN 62.20
- Support Level
- TSI $4.85
- HLN $10.57
- Resistance Level
- TSI $4.93
- HLN $10.85
- Average True Range (ATR)
- TSI 0.04
- HLN 0.13
- MACD
- TSI 0.01
- HLN 0.05
- Stochastic Oscillator
- TSI 84.62
- HLN 94.77
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About HLN Haleon plc (Each representing two)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.